EGFR is another kinase that phosphorylates PARP1 [63], and the inhibition of both EGFR and PARP1 results in synthetic lethality in highly aggressive triple negative breast cancers (TNBCs). The gene discussed is EGFR; the disease is triple-negative breast carcinoma.